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Abstract  29 
Aim 30 
To evaluate the evidence for denosumab for the treatment of bone metastases secondary to 31 
solid tumours and, using a network meta-analysis, indirectly compare denosumab with 32 
bisphosphonates and best supportive care. 33 
Data sources 34 
MEDLINE (1948 to April 2011), EMBASE (1980 to March 2011), Cochrane Library (all 35 
sections) (Issue 1, 2011) and Web of Science with Conference Proceedings (1970 to May 36 
2011) and additional meeting abstracts (2010 and 2011) were searched. 37 
Study eligibility, participants and interventions 38 
Only randomised controlled trials assessing denosumab, bisphosphonates or best 39 
supportive care in patients with bone metastases from any solid tumour were included. 40 
Synthesis 41 
Direct evidence comparing denosumab and zoledronic acid was assessed for breast cancer, 42 
prostate cancer and other solid tumours. Denosumab was compared with pamidronate and 43 
best supportive care through a network meta-analysis for each tumour type. The primary 44 
outcomes were time to first skeletal related event (SRE) and time to first and subsequent 45 
SRE. Secondary outcomes were skeletal morbidity rate, pain, quality of life (QoL) and overall 46 
survival. 47 
Results 48 
Denosumab was found to be more effective in delaying the time to first SRE and reducing 49 
the risk of first and subsequent SREs compared to zoledronic acid, placebo and 50 
pamidronate. In breast and prostate cancer, denosumab was effective in reducing skeletal 51 
morbidity rate compared with placebo. The lack of published data on pain and QoL meant 52 
that firm conclusions could not be made. Denosumab did not appear to have an affect on 53 
overall survival. 54 
Limitations 55 
Network meta-analyses are subject to uncertainties and potential biases. 56 
Conclusions 57 
Denosumab is effective in preventing SREs, but the effect on pain and QoL is unclear.  58 
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Introduction 63 
The impact of bone metastases on cancer patients can be considerable. Complications, 64 
reduced mobility, pain and the effects of treatment reduce quality of life significantly. 65 
Complications may include pathological fracture, spinal cord compression and 66 
hypercalcaemia of malignancy.  67 
Bone-targeted pharmacological treatments aim at preventing complications, reducing pain 68 
and improving quality of life. To date bisphosphonates have been the main pharmacological 69 
treatment option for patients with bone metastases. Currently licensed bisphosphonates 70 
include; zoledronic acid (any advanced malignancy involving bone), disodium pamidronate 71 
(breast cancer or multiple myeloma), sodium clodronate (breast cancer or multiple myeloma) 72 
and ibandronic acid (breast cancer). Bisphosphonates are administered either intravenously 73 
(zoledronic acid, pamidronate or ibandronic acid) or orally (clodronate or ibandronic acid) 74 
and have been associated with renal toxicity.1 In the UK, the National Institute of Health and 75 
Clinical Excellence (NICE) currently recommends the use of bisphosphonates in all patients 76 
with bone metastases secondary to breast cancer,2 patients with hormone resistant prostate 77 
cancer with painful bone metastases despite conventional analgesics3 or as an option in 78 
lung cancer with bone metastases.4 Patients who are not recommended for 79 
bisphosphonates would receive standard best supportive care. 80 
Denosumab (Xgeva, Amgen) is a fully human monoclonal antibody, licensed for the 81 
prevention of skeletal related events (SRE) in bone metastases from solid tumours. It is 82 
administered by sub-cutaneous injection and does not require renal monitoring.5   83 
The term ‘skeletal related event’ is a composite endpoint that has evolved over the past 20 84 
years for use in clinical trials. Recent trials define SREs as pathological fracture (including 85 
asymptomatic vertebral collapse), spinal cord compression or need for radiotherapy or 86 
surgery to bone.6-8  Other definitions have included hypercalcaemia or change in anti-87 
neoplastic therapy. 88 
Three pivotal trials have evaluated denosumab compared to zoledronic acid for the 89 
prevention of SREs.6-8 There are no head-to-head trials of denosumab compared with other 90 
bisphosphonates or best supportive care. These comparisons are, nonetheless, important 91 
because of the wide variation in practice. Some centres use only zoledronic acid, some use 92 
a variety of bisphosphonates, while others do not use bisphosphonates at all (especially in 93 
cancer other than breast). Therefore the aim of this review is to evaluate the evidence for 94 
denosumab for the treatment of bone metastases in solid tumours and, using a network 95 
meta-analysis, indirectly compare denosumab with other bisphosphonates and best 96 
supportive care.  97 
Materials and methods 98 
 99 
The review complies with PRIMSA guidelines.9 A pre-specified protocol has been published 100 
on the NICE website.10  101 
 102 
Literature search and eligibility criteria 103 
Studies were identified by systematic searching of the following databases; MEDLINE (1948 104 
to April 2011), EMBASE (1980 to March 2011), Cochrane Library (all sections) (Issue 1, 105 
2011) and Web of Science with Conference Proceedings (1970 to May 2011). Additional 106 
meeting abstracts (2010 and 2011) were identified through searching American Society of 107 
Clinical Oncology, American Urological Association and San Antonio Breast Cancer 108 
symposium. Reference lists of all included studies were scanned to identify additional 109 
potentially relevant studies. The titles and abstracts of all papers identified by the search 110 
strategy were screened and full-text copies of all potentially relevant studies obtained. 111 
 112 
The search strategy used for MEDLINE was; step 1) exp Diphosphonates, step 2) RANK 113 
Ligand, step 3) (denosumab or bisphosphonate* or ibandron* or clodron* or pamidron* or 114 
zoledron*).tw., step 4) (radiation or radiotherapy or radionuclide* or hormone therapy or 115 
strontium or samarium).ti., step 5) or/1-4, step 6) exp Neoplasms, step 7) (solid tumor or 116 
solid tumour* or cancer or carcinoma or myeloma).tw., step 8) or/6-7, step 9) 5 and 8, step 117 
10) exp Bone Neoplasms, step 11) (((bone or osteolytic or lytic) adj lesion*) or (bone adj2 118 
metast*)).tw., step 12) (skeletal or fracture*).tw., step 13) or/10-12, step 14) 9 and 13, step 119 
15) randomized controlled trial.pt., step 16) 14 and 15 and, step 17) limit 16 to english 120 
language. 121 
 122 
This search strategy was adapted as appropriate for the other databases 123 
 124 
Only randomised controlled trials evaluating denosumab, bisphosphonates or best 125 
supportive care were included. Best supportive care included trials evaluating radiotherapy, 126 
radionuclides, hormone therapy, strontium or samarium.  Bone metastases secondary to any 127 
solid tumour were eligible.  128 
 129 
Screening was performed by two independent authors and disagreements resolved by 130 
discussion. After piloting a data extraction form, data were extracted by one author and 131 
checked by a second. Data included study characteristics, inclusion/exclusion criteria, 132 
results and adverse events. Quality was assessed using the Cochrane risk of bias tool.11 133 
 134 
The primary outcomes were time to first SRE and time to first and subsequent SRE. 135 
Secondary outcomes were skeletal morbidity rate (SMR, , defined as ratio of the number of 136 
SREs per patient divided by the patient’s time at risk), pain, quality of life and overall 137 
survival. 138 
  139 
Network meta-analysis 140 
Network meta-analysis (NMA) is a statistical technique used to indirectly compare two or 141 
more interventions. Generally, it is used in situations where there is an absence of head-to-142 
head trials.  143 
Studies meeting the inclusion criteria were assessed for eligibility of synthesis by network 144 
meta-analysis, by evaluating methodological heterogeneity. To be suitable for NMA, studies 145 
were required to be similar with respect to population, intervention, comparators, outcomes, 146 
SRE definition and time frame. Based on this assessment, networks were designed.  147 
Networks were created for three primary cancer types; breast cancer, prostate cancer and 148 
other solid tumours including (OST). A subgroup of patients with non small cell lung cancer 149 
within OST was also explored. 150 
The analyses followed methods for mixed treatment comparisons described by Lu and 151 
Ades.12 and used the Bayesian software package, WinBUGS, which employs Markov chain 152 
Monte Carlo (MCMC) methods. 153 
Outcomes analysed were time to first SRE (hazard ratios), time to first and subsequent SRE 154 
(rate ratios from Andersen-Gill13 multiple event analyses reported in primary studies) and 155 
SMR ratios (for breast and prostate cancer only).   156 
Fixed effects models were used for time to first SRE, adopting an approach recommended 157 
by the NICE Decision Support Unit14 for modelling trial-based summary measures, which 158 
can be applied to modelling hazard ratios on the log hazard scale.  The trial-level data 159 
included in the models comprised log hazard ratios and its standard error.  Where hazard 160 
ratios were not reported or derivable in the primary study or related publications (e.g. 161 
publically available FDA documentation), Kaplan-Meier estimates and numbers at risk (if 162 
available) were used, applying the methods of Tierney15 to estimate the hazard ratio.  163 
Pairwise hazard ratios were estimated from the median of the posterior distribution with 164 
credible intervals taken from the 2.5% and 97.5% percentiles.  Ten thousand MCMC 165 
simulations were used in the analysis following a burn-in of 10,000.  The same approach 166 
was taken for modelling rate ratios in the analysis of time to first and subsequent SREs.   167 
For SMR a random effects model was adopted using arm-based data.  The data included in 168 
the SMR models were mean SMR and standard deviation along with the number of patients.  169 
Where standard deviations were not reported, values were imputed by taking the mean of 170 
reported SDs from other studies but for the same treatment.  The robustness of the 171 
imputation was tested by comparing results with those obtained by treating missing data as 172 
an uncertain parameter.  Posterior distributions for relative treatment effects were estimated 173 
from the absolute risks of outcome from the relevant individual treatments.  Median 174 
estimates and credible intervals were taken from 10,000 MCMC simulations after a burn-in 175 
of 10,000.      176 
In order to estimate the absolute risk of outcome in the analyses of arm-based data, it was 177 
necessary to include an estimate of the baseline risk of the control treatment in the models.  178 
Zoledronic acid was treated as the reference treatment in each analysis as it is the treatment 179 
common to the largest number of trials and is present in multiple included studies for each 180 
NMA.  Single-arm meta-analyses of zoledronic acid were conducted to estimate baseline 181 
risk from studies included in the NMA that had zoledronic acid as one of its comparators.  182 
The data in the time-to-event analyses, however, were trial-based and baseline risk could 183 
not be estimated so the absolute effect of the reference treatment was set to zero in these 184 
models. 185 
The quality of the models was examined by inspecting convergence using Gelman-Rubin-186 
Brooks plots, assessing autocorrelation between iterations of the Markov chain and checking 187 
whether the MC error was less than 5% of the posterior standard deviation.  188 
Results 189 
 190 
Literature search 191 
Results of the literature search are shown in figure 1. Thirty-eight studies met the inclusion 192 
criteria, most of which compared bisphosphonates with placebo. Of these 38 studies, 30 193 
were excluded because they were not suitable for network meta-analysis (table 1). The 194 
characteristics and results of the eight studies included in the NMA are shown in table 2 and 195 
3.  196 
 197 
Study quality 198 
The quality of the studies included in the NMA was high as shown in table 4. There was a 199 
low risk of bias for the majority of categories. Stopeck 20108 and Rosen 200316 failed to 200 
describe sequence generation or allocation concealment. Kohno 200517 and Rosen 200316 201 
did not sufficiently address incomplete outcome data. 202 
 203 
Study characteristics 204 
Four studies included patients with breast cancer,8,16-18 two with prostate cancer6,19 and two 205 
with other solid tumours7,20 (table 2). Henry 2011 included patients with multiple myeloma, in 206 
addition to patients with other solid tumours. Three studies compared denosumab with 207 
zoledronic acid,6-8 three compared zoledronic acid with placebo,17,19,20 one zoledronic acid 208 
with pamidronate16 and one pamidronate with placebo.18  209 
Six studies were international, one study only recruited patients from Japan17 and one study 210 
recruited patients from the US.18 Patients were youngest in the breast cancer studies and 211 
oldest in the prostate. The proportion of patients with a previous SRE at baseline ranged 212 
from 24%6 to 73%.20  213 
 214 
Direct SRE results 215 
Denosumab statistically significantly delayed the time to first on-study SRE in breast cancer, 216 
prostate cancer and other solid tumours (table 3). The difference in mean months of time to 217 
first SRE between denosumab and zoledronic acid was 3.6 months in prostate cancer (HR 218 
0.82 95%CI 0.71 to 0.95) and 4.3 months in other solid tumours (HR 0.84 95%CI 0.71 to 219 
0.98) (in breast cancer this outcome was not reached (HR 0.82 9%%CI 0.71 to 0.95)). 220 
Similarly, denosumab statistically significantly reduced the risk of time to first and 221 
subsequent SRE for prostate cancer (rate ratio 0.82 95%CI 0.71 to 0.94) and breast cancer 222 
(rate ratio 0.77, 95%CI 0.66 to 0.89). In other solid tumours, the result favoured denosumab 223 
but was not statistically significant (rate ratio 0.90 95%CI 0.77 to 1.04).  224 
Stopeck 20108 was the only trial evaluating denosumab to report SMR. Denosumab was 225 
associated with a lower SMR compared with zoledronic acid (0.45 compared with 0.58, p 226 
value 0.004) in patients with breast cancer.  227 
In the bisphosphonate trials, zoledronic acid and pamidronate were associated with delayed 228 
time to first SRE, time to first and subsequent SRE and SMR. In the only trial comparing 229 
zoledronic acid and pamidronate,16 the authors found that zoledronic acid statistically 230 
significantly reduced the time to first SRE in hormone-treated breast cancer patients (415 231 
days versus 370 days, p = 0.047) and risk of time to first and subsequent SRE in all breast 232 
cancer patients (RR = 0.80 (0.66 to 0.97). 233 
 234 
Pain study results 235 
Stopeck 20108 reported that the median time to developing moderate/severe pain in women 236 
with breast cancer, in patients with no/mild pain at baseline, was longer in denosumab 237 
compared with zoledronic acid (295 days versus 176 days; HR 0.78, 95%CI 0.67 to 0.92) 238 
Pain outcomes for denosumab compared with zoledronic acid in other solid tumours is 239 
available in abstract form.21 Denosumab was found to delay the time to clinically significant 240 
pain (more than 2 point increase from baseline on brief pain inventory) compared to 241 
zoledronic acid (169 days compared with 143 days HR 0.85, 95% CI: 0.73-0.98). 242 
In prostate cancer, pain data have also been published in abstract form.22 In the subgroup of 243 
patients with no/mild pain at baseline, there was no statistically significant difference in the 244 
time to moderate/severe in denosumab compared to zoledronic acid (177 days versus 148 245 
days; HR 0.89, 95% CI 0.77, 1.04).  246 
 Quality of life study results 247 
In breast cancer, quality of life data for denosumab have been published in abstract form.23 248 
The authors report that over the 18 month period an average of 4.1% more (range -0.6% to 249 
9.3%) patients treated with denosumab, compared with zoledronic acid, experienced a 250 
meaningful improvement in quality of life (5 or more increase in FACT-G score). 251 
No quality of life data are available for prostate cancer or other solid tumours. 252 
 253 
Overall survival study results 254 
There was no significant difference in overall survival between denosumab and zoledronic 255 
acid in breast cancer and prostate cancer. Henry 201024 also reported no significant 256 
difference; however on ad hoc analysis the authors found that denosumab was associated 257 
with an increased overall survival in non small cell lung cancer (HR 0.79, 95%CI 0.65 to 258 
0.95). Notably the authors also reported a decrease in overall survival in the ad hoc analysis 259 
of multiple myeloma patients (HR 2.26, 95%CI 1.13 to 4.50). 260 
 261 
Safety 262 
For breast, prostate and other solid tumours denosumab, compared with zoledronic acid, 263 
was associated with lower renal impairment (0.4% versus 2.2%, 16% versus 15%, 8.3% 264 
versus 10.9%) and acute phase reaction (10.4% versus 27.3%, 8% versus 18%, 6.9% 265 
versus 14.5%). However, denosumab was associated with higher incidence of 266 
hypocalcaemia (not reported, 13% versus 6%, 2.3% versus 1.0%) and osteonecrosis of the 267 
jaw (2.0% versus 1.4%, 2 versus 1%, 1.1% versus 1.3%). 268 
 269 
Network meta-analysis results 270 
Network diagrams for breast cancer, prostate cancer and other solid tumours are shown in 271 
figures 2, 3 and 4. The same network was used for the subgroup of non small cell lung 272 
cancer as other solid tumours.  The results of these analyses are summarised in tables 5, 6 273 
and 7.   274 
Denosumab versus placebo 275 
NMA results suggest that denosumab, compared with placebo, reduces the time to first SRE 276 
in breast, prostate cancer and other solid tumours. In non small cell lung cancer the result 277 
favoured denosumab, but was not statistically significant (HR 0.68, 95%CI 0.45 to 1.03). 278 
Similarly denosumab statistically significantly reduced the risk of first and subsequent SRE in 279 
breast cancer, prostate cancer, other solid tumours and non small cell lung cancer, 280 
compared to placebo. Additionally, denosumab reduced the skeletal morbidity rate 281 
compared with placebo in all groups.  282 
Denosumab versus pamidronate 283 
The comparison of denosumab versus pamidronate was only possible in breast cancer. For 284 
skeletal morbidity rate the result favours denosumab, but there was no significant difference. 285 
There was a significant difference in time to first SRE and time to first and subsequent SRE 286 
when denosumab was compared with pamidronate (HR 0.73 95%CI 0.56 to 0.94 and rate 287 
ratio 0.62 95%CI 0.48 to 0.80, respectively).  288 
Discussion 289 
 290 
Statement of key findings 291 
Based on the review of direct evidence and network meta-analysis, denosumab, compared 292 
with zoledronic acid or placebo, statistically significantly delays time to first SRE, time to first 293 
and subsequent SRE and skeletal morbidity rate. Denosumab appears to be more effective 294 
than pamidronate for these outcomes, but the results have mixed statistical significance.  295 
Although denosumab has demonstrated its effectiveness in delaying SREs, a lack of 296 
published data means that conclusions about pain and quality of life cannot be made. There 297 
was no statistically significant difference in overall survival for denosumab compared with 298 
zoledronic acid for prostate and breast cancer. However in an ad hoc analysis of the trial 299 
including various tumour types, denosumab was found to improve the overall survival in non-300 
small cell lung cancer.  301 
 302 
Strengths and limitations 303 
There are a number of strengths of this review. A comprehensive and robust search strategy 304 
was used. A rigorous inclusion/exclusion criteria was used which only included high quality 305 
evidence (RCTs). Undertaking a NMA means that estimates of effectiveness can be made 306 
when no direct evidence is available. This was the case for comparing denosumab with 307 
placebo and pamidronate. Excluding studies with a different definition of what constitutes an 308 
SRE resulted in a smaller but more robust NMA. 309 
Although NMA allows indirect estimates to be calculated, they can be subject to potential 310 
biases and uncertainties.25 Network meta-analyses are not randomised comparisons, but 311 
rather observational findings across studies and therefore should be interpreted with due 312 
caution. The quality of any NMA is only as good as the weakest link in the network. All 313 
studies included in this NMA were of good quality (table 4), improving the validity of the NMA 314 
results. Some published studies did not report full results, therefore some treatment effects 315 
were estimated, for example using the method described by Teirney and colleagues.15 316 
However when these parameters were treated as uncertain, the impact on the results was 317 
negligible. A key limitation was the small number of studies included. This resulted in an 318 
unstable model when a random effects model was used for time to first SRE and time to first 319 
and subsequent SRE. Therefore a fixed effects model was used, which assumes no 320 
variability between studies. 321 
 322 
 323 
Meaning of the results 324 
Our analysis indicates that denosumab is effective in delaying first and first-and-subsequent 325 
SREs when compared to zoledronic acid, placebo and pamidronate. NMA analysis results in 326 
reduced power and therefore less precision. Non-statistically significant results for skeletal 327 
morbidity rate for denosumab compared with pamidronate should not be interpreted as 328 
evidence that there is no effect. Only if higher powered NMA were possible could this 329 
conclusion be made. 330 
The validity of these results relies on, firstly, the SRE outcome and, secondly, the analysis of 331 
it. The SRE outcome is useful because it allows for increased power and therefore 332 
efficiency. It would be impractical to power trials to detect differences in each component of 333 
the SRE outcome, especially with regard to spinal cord compression and need for surgery to 334 
bone (as these are rare events). However, the composite outcome is of little use to patients 335 
since it incorporates a wide spectrum of clinical events, ranging from asymptomatic 336 
pathological fracture (identified during routine on-study skeletal surveys) to paraplegic spinal 337 
cord compression. Furthermore, the outcome does not directly measure mobility or bone 338 
pain, although it could be argued that the need for radiotherapy is an indirect measure of 339 
bone pain. In addition, for many patients, radiotherapy will be a highly effective treatment for 340 
bone pain. 341 
Using time to event and multiple event analyses (time to first and subsequent SRE) allows 342 
smaller differences between treatments to be identified. This may be warranted when 343 
comparing active comparators; however, researchers and healthcare staff should ensure 344 
that statistically significant differences are clinically meaningful. In addition, the method used 345 
in these trials for the multiple event analysis (Andersen-Gill13) has been criticised because it 346 
does not differentiate between participants who died and who leave the study for another 347 
reason.26 These issues have been discussed in greater detail elsewhere.27  348 
A key issue is whether the delay in SREs results in a reduction in pain and improvement in 349 
quality of life. Ideally, the improved SRE outcomes with denosumab, would be interpreted 350 
alongside pain and quality of life data. Unfortunately, the lack of published pain and quality 351 
of life data means that this association could not be established. The data published from the 352 
three pivotal trials are only available in abstract form and generally only reports subgroups. 353 
For breast cancer there was a statistically significant delay to moderate/severe pain in 354 
patients with no/mild pain, however in prostate cancer the difference was not statistically 355 
significant.   356 
Denosumab has the added advantage of being given as a sub-cutaneous injection which 357 
does not require renal monitoring. Denosumab could potentially be administered in the 358 
community. Zoledronic acid is an intra-venous administration and requires renal monitoring 359 
with dose adjustment if renal impairment present. In terms of adverse events, denosumab 360 
has lower renal toxicity and does not appear to be associated with acute phase reactions. 361 
However, there is a marginally higher incidence of osteonecrosis of the jaw. In addition, 362 
there is a higher incidence of hypocalcaemia but this can be easily corrected with 363 
appropriate treatment.  364 
 365 
Future research needs 366 
In common with most findings for bisphosphonates in advanced cancer, from available 367 
evidence denosumab does not appear to affect overall survival. In the Henry 2010 trial,24 368 
there was a statistically significant improvement in overall survival in the ad hoc analysis for 369 
non small cell lung cancer. The reason for this is not clear and it may be a chance finding. 370 
Further trials in this subgroup would be needed to establish the validity of this result.. 371 
The place for denosumab in treatment pathways is unclear. Much of this will depend on local 372 
budgets and on economic evaluations.28,29 One option may be as a second line agent in 373 
patients who suffer an SRE on bisphosphonates. A randomised controlled trial looking at this 374 
specific population may be informative. 375 
 376 
Conclusion 377 
Denosumab compared with zoledronic acid, placebo and, pamidronate, is effective in 378 
delaying time to first SRE and reducing the risk of first and subsequent SRE. However, 379 
conclusion about its impact on pain reduction and quality of life cannot be reached because 380 
of the lack of published data.  381 
 382 
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Table 1: Studies meeting inclusion criteria but unsuitable for NMA 679 
Primary 
tumour 
Study ID Intervention Comparator Reason for exclusion 
BP vs placebo/ another BP 
(n=27) 
Breast   Body 2004
30
 
Body 2004
31
 
Tripathy 2004
32
 
Ibandronate (oral) Placebo  SRE definition not 
comparable 
Body 2003,
33
 
Diel 2004
34
 
Ibandronate (iv) Placebo  SRE definition not 
comparable 
Heras 2009
35
 Ibandronate (iv) Placebo SRE definition not 
comparable 
Elomaa 1988
36
 Clodronate (oral) Placebo SRE definition not 
comparable 
Paterson 1993
37
 Clodronate (oral) Placebo SRE definition not 
comparable 
Kristensen 
1999
38
 
Clodronate (oral) Open  SRE definition not 
comparable 
Prostate Dearnaley 
2003
39
  
Clodronate (oral) Placebo  Hormone sensitive prostate 
cancer 
Elomaa 1992
40
 Clodronate (iv) Placebo Only painful metastases 
Kylmala 1993
41
 Clodronate (iv) Open Only painful metastases 
Ernst 2003
42
 Clodronate (iv) Placebo Unlicensed administration of 
clodronate 
Adami 1989,
43
 
Adami 1985
44
 
Clodronate 
(iv+im+oral) 
Placebo Only painful metastases 
Kylmala 1997
45
 Clodronate 
(iv+oral) 
Placebo Only painful metastases 
Strang 1997
46
 Clodronate (iv) Placebo Only painful metastases 
Small 2003
47
 Pamidronate (iv) Placebo Only painful metastases 
Smith 1989
48
 Etidronate (iv+oral) Placebo Only painful metastases 
OST Arican 1999
49
 Clodronate (oral)  Placebo  SRE definition not 
comparable 
Brown 2007
50
 Clodronate (oral) Placebo Outcomes not relevant 
O’Rourke 1995
51
 Clodronate (oral) Placebo Outcomes not relevant 
Piga 1998
52
 Clodronate (oral) Placebo Outcomes not relevant 
Robertson 
1995
53
 
Clodronate (oral) Placebo SRE definition not 
comparable 
Jagdev 2001
54
 Clodronate (oral) Pamidronate 
(iv) 
Outcomes not relevant 
Mystakidou 
2008
55
 
Ibandronate (oral)  Ibandronate 
(iv) 
Outcomes not relevant 
Heras 2007
56
 Ibandronate  (iv) Placebo SRE definition not 
comparable 
Berenson 
2001
57
 
Zoledronic acid (iv)  Pamidronate 
(iv) 
SRE definition not 
comparable 
Zaghloul 2010
58
 Zoledronic acid (iv) Placebo SRE definition not 
comparable 
Zhao 2011
59
 Zoledronic acid (iv) Open  SRE definition not 
comparable 
Primary 
tumour 
Study ID Intervention Comparator Reason for exclusion 
BSC vs placebo/ another BSC 
(n=4) 
Prostate 
  
Buchali 1988
60
 Strontium chloride 
(iv) 
Placebo SRE definition not 
comparable 
Nilsson 2005
61
 Strontium chloride 
(iv) 
FEM Only painful metastases 
Porter 1993
62
 Strontium chloride 
(iv) 
Placebo Only painful metastases 
Quilty 1994
63
 Strontium chloride 
(iv) 
Radiotherapy  Only painful metastases 
 680 
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Table 2: Characteristics of studies included in NMA 682 
Author, 
year, 
country 
and 
duration 
Cancer 
type 
Intervention
s 
Participants Outcomes Comments 
Age Prev 
SRE, n 
(%) 
Kohno 
2005
17
 
Country: 
Japan 
Duration
: 12 
months 
 
Breast Zoledronic 
acid 4 mg 
(n=114) 
 
mean 54.3 39 (34.2) SRE outcomes 
Ratio of SRE rate (defined as the total number of SREs divided by 
the total years on study) for patients treated with zoledronic acid 
divided by the SRE rate for the placebo group  (excluding HCM in 
definition)   
Proportion of patients experiencing at least one SRE  
Time to first SRE 
Multiple-event analysis by the Andersen-Gill method 
Risk ratio for developing SREs 
Other outcomes 
Change from baseline BPI composite pain scores and bone 
resorption markers 
Both 
administered via 
15-minute 
infusion. 
Infusions were 
administered 
every 4 weeks 
for 12 months 
Placebo 
(n=113) 
mean 53.5 47 (41.6) 
Lipton 
2000
18,64-
66
 
Country: 
US 
Duration
: 24 
months 
(24 
cycles) 
Breast Pamidronate  
90 mg  
(n=367) 
 
<50 years 25%  
51-65 years 
42%  
>65 years 33% 
NR SRE outcomes 
SMR (number of skeletal complications per time on trial for each 
patient (events/year); the overall SMR was calculated with and 
without hypercalcemia counted as a skeletal complication  
Proportion of patient with skeletal complications 
Time from randomisation to first SRE   
Other outcomes 
Bone pain score,  analgesic use, ECOG performance status and 
quality of life  measured as mean change from baseline to 24 
months or last visit (any time during study);   
Overall survival 
Both 
administered in 
250 mL of 5% 
dextrose in 
water given as a 
2-hour 
intravenous 
infusion every 3-
4 weeks for 24 
cycles. 
 
Placebo  
(n=384) 
<50 years 29%  
51-65 years 
38%  
>65 years 34% 
NR 
Rosen 
2003a
16,6
7,68
 
Country:  
Multinati
onal  
Duration
: 25 
Breast 
cancer 
 
Zoledronic 
acid 4 mg 
(n=378) 
 
median 58 232 (61.4) SRE outcomes 
Proportion of patients who experienced at least 1 SRE during 25 
month study period (HCM not included).  
Proportion of patients experiencing any SRE (including HCM) 
Time to first SRE 
SMR* 
Multiple-event analysis* 
Other outcomes 
Both 
administered as 
an intravenous 
infusion 
depending on 
the scheduling of 
other 
antineoplastic 
Pamidronate 
90 mg  
(n=388) 
 
median 56 244 (62.9) 
months  None reported treatments every 
3–4 weeks for 
24 months 
Stopeck 
2010
8,69-
75
 
Country: 
Multinati
onal 
Duration
: 34 
months 
Breast Denosumab 
120 mg 
(subcutaneo
us injection) 
+  placebo 
(intravenous 
infusion)  
(n=1026) 
mean 57 378 (36.8) SRE outcomes 
Time to first on-study SRE (non-inferiority test) 
Time to first on-study SRE (superiority test)  
Time to first and subsequent on-study SREs (multiple event 
analysis).  
[Subsequent events must have occurred at least 21 days apart from 
the most recent event to ensure that linked events (eg, surgery to 
repair a fracture or multiple doses of radiation during a course of 
treatment) were not counted as separate SREs.] 
Other outcomes 
Overall survival 
Disease progression  
Skeletal morbidity rate  
Percent change in uNTx and BSAP levels. 
 
Intravenous 
products 
(placebo or 
zoledronic acid) 
were dose-
adjusted on the 
basis of baseline 
creatinine 
clearance   60 
mL/min and 
were held for 
renal function 
deterioration on-
study  as per 
zoledronic acid 
prescribing 
information 
Zoledronic 
acid 4 mg 
(intravenous 
infusion) + 
placebo 
(subcutaneo
us injection)    
(n=1020) 
mean 56 373 (36.6)   
Fizazi 
2011
6
 
Country: 
Multinati
onal  
Duration
:  27 
months 
Prostate Denosumab 
120 mg 
(subcutaneo
us) + 
placebo  
(n=950) 
median 71 232 (24) SRE outcomes 
Time to first on-study skeletal-related event; assessed for non-
inferiority 
If testing of the primary endpoint showed non-inferiority, then the 
same outcome was further tested as a secondary endpoint, 
together with the secondary endpoint of time to first and subsequent 
on-study skeletal-related events (multiple events), for superiority 
Other outcomes 
Overall survival  
Overall disease progression  
Prostate-specific antigen concentration during the study 
Change in bone turnover markers from baseline  
Pain 
Interventions 
given every 4 
weeks until the 
primary analysis 
cut off date. 
Dose adjustment 
as per Stopeck 
2010 
Zoledronic 
acid 4 mg + 
placebo 
(subcutaneo
us)  
(n=951) 
median 71 231 (24) 
Saad 
2002
19,76-
82
 
Country: 
Multinati
onal 
Prostate Zolendronic 
acid 4mg  
(n=214) 
 
mean 72 66 (30.8) SRE outcomes 
The proportion of patients having at least one skeletal-related event 
Time to the first skeletal- related event  
Skeletal morbidity rate Proportion of patients with individual 
skeletal-related events 
Other outcomes 
Administered 
every 3 weeks 
for 15 months 
(20 cycles). 
Initially 5 min 
infusion (in 
Placebo mean 72 78 (37.5) 
Duration
: 15 
months 
(n=208) 
 
Time to disease progression  
Objective bone lesion response 
 Bone biochemical markers   
Quality-of-life parameters  
Pain 
50ml), changed 
to 15 min 
infusion (in 
100ml) in 1999 
 
Henry 
2011
7,21,2
4
 
Country: 
Multinati
onal 
Duration
: 7 
months 
(median 
time on-
study 
Other 
solid 
tumours 
Denosumab  
120 mg  
(n=890) 
 
median 61 446 (50) SRE outcomes 
Time to first on-study SRE (non-inferiority) 
Time to first on-study SRE (superiority tests)   
Time to first-and-subsequent SRE (multiple-event analysis). 
Other outcomes 
Bone turnover markers  
Overall survival 
Overall disease progression. 
 
Zoledronic acid 
administered 
intravenously 
monthly with 
subcutaneous 
placebo.  
 
Zoledronic 
acid 4 mg 
(n=886) 
 
median 60 440 (50) 
Rosen 
2003b
20,8
3,84
 
Country: 
Multinati
onal 
Duration 
of study: 
9 
months 
Other 
solid 
tumours 
Zoledronic 
acid 4 mg  
(n=257) 
 
median 64 166 (65) SRE outcomes 
Proportion of patients with at least one SRE 
Time to first SRE 
SMR (defined as the number of SREs per year) Multiple event 
analysis 
Other outcomes 
Pain score 
Analgesic use  
ECOG performance status 
Best bone lesion response and time to progression of bone lesions 
Biochemical markers of bone resorption 
Time to progression of overall disease and survival.  
Quality of life  
Interventions 
administered 
intravenously 
every 3 weeks 
for 9 months Placebo 
(n=250) 
 
median 64 179 (73) 
 683 
  684 
Table 3: Results of individual studies included in the NMA 685 
Cancer Study Intervention TTF SRE  p value TTF+S SRE SMR p 
value 
Breast Kohno 
200517 
Zoledronic acid 
(n=114) 
Not reached N/R 0.007 RR 0.59 (0.38 
to 0.91) 
0.63 0.016 
Placebo (n=113) 364 days (~12.1 months) 1.1 
Lipton 
200018 
Pamidronate (n=367) 12.7 months (95%CI 9.6 to 
17.2) 
N/R <0.001 NR 2.4 (5.5) <0.001 
Placebo (n=387) 7.0  months (95%CI 6.2 to 
8.5) 
3.7 (5.5) 
Rosen 
2003a16 
Zoledronic acid 
(n=378) 
349 days(chemo treated) 
415 days(hormone treated) 
N/R 0.826 
(chemo) 
0.047 
(hormone) 
RR = 0.80 (0.66 
to 0.97) 
0.9 0.125 
Pamidronate (n=388) 366 days (chemo treated) 
370 days(hormone treated) 
1.49 
Stopeck 
20108 
Denosumab 
(n=1026) 
 Not reached HR 0.82 
95%CI 0.71 
to 0.95 
<0.001 RR *0.77 (0.66 
to 0.89) 
0.45 0.004 
Zoledronic acid 
(n=1020) 
26.4 months 0.58 
Prostate Fizazi 
20116 
Denosumab (n=950) 20.7 months HR 0.82, 
95%CI 0.71 
to 0.95  
0.0002 RR* 0.82 (95% 
CI 0.71 to 0.94) 
NR NR 
Zoledronic acid 
(n=951) 
17.1 months NR 
Saad 
200219 
Zoledronic acid 
(n=214) 
 
361 days (prev SRE) 
499 days (no prev SRE) 
N/R 0.066 
(prev 
SRE) 
0.065 (no 
prev SRE) 
RR 0.64 (95% 
CI not reported, 
p value 0.002) 
0.80 0.006 
Placebo (n=208) 
 
258 days (prev SRE) 
337 days (no prev SRE) 
1.49 
Other 
solid 
tumours 
Henry 
20117 
Denosumab (n=886) 20.6 months HR 0.84, 
95%CI 0.71 
to 0.98 
0.0007 RR*† 0.90 (0.77 
to 1.04) 
NR NR 
Zoledronic acid 
(n=890) 
16.3 months NR 
Rosen  
200320 
Zoledronic acid 230 days N/R 0.023 HR 0.732, 
p=0.017 
2.24 0.069 
Placebo 163 days 2.52 
RR = risk ratio, RR* = rate ratio, HR = hazard ratio, † = includes multiple myeloma, N/R = not reported, TTF SRE = time to first skeletal related 686 
event, TTF+S SRE = time to first and subsequent skeletal related events 687 
Table 4: Risk of bias of studies included in NMA 688 
Study id Q1 Adequate 
sequence 
generation? 
Q2 Adequate 
allocation 
concealment? 
Q3 Blinding? Q4 Incomplete 
outcome data 
addressed? 
Q5 Free of selective 
reporting? 
Breast cancer 
Lipton 200018 Low Low Low Unclear Unclear 
Kohno 200517 Low Low Low High Low 
Stopeck 20108 Unclear Unclear Low Low Low 
Rosen 2003a16 Low Low Low Low Low 
Prostate cancer 
Fizazi 20116 Low Low Low Low Low 
Saad 200219 Low Low Low Low Low 
Other solid tumours 
Henry 20117 Low Low Low Low Low 
Rosen 2003b20 Unclear Unclear Low High Low 
 689 
 690 
Table 5: Breast cancer NMA results 
Comparison TTF SRE  
HR (95% CI) 
TTF+S Risk 
Ratio (95% CI) 
SMR 
Rate Ratio (95% CI) 
Denosumab versus 
zoledronic acid 
0.82 (0.71 to 
0.95) 
0.77 (0.66 to 
0.89) 
0.90 (0.67 to 1.09) 
Denosumab versus 
pamidronate 
0.79 (0.61 to 
1.03) 
0.62 (0.48 to 
0.80) 
0.73 (0.41 to 1.06) 
Denosumab versus 
placebo  
0.46 (0.29 to 
0.72) 
0.45 (0.28 to 
0.72) 
0.47 (0.25 to 0.67) 
Zoledronic acid versus 
placebo 
0.56 (0.36 to 
0.86) 
0.59 (0.37 to 
0.91) 
0.52 (0.32 to 0.70) 
 
TTF SRE = time to first skeletal related event, TTF+S SRE = time to first and subsequent 
skeletal related events, SMR = skeletal morbidity rate  
 
  
Table 6: Prostate cancer NMA results 
 TTF SRE 
HR (95%CI) 
TTF+S Risk 
Ratio (95% CI) 
SMR 
Rate Ratio (95% CI) 
Denosumab versus 
zoledronic acid 
0.82 (0.71 to 
0.95) 
0.82 (0.71 to 
0.94) 
0.95 (0.46 to 1.47) 
Denosumab versus 
placebo 
0.56 (0.40 to 
0.77) 
0.53 (0.39 to 
0.72) 
0.52 (0.07 to 0.82) 
Zoledronic acid versus 
placebo 
0.68 (0.50 to 
0.91) 
0.64 (0.48 to 
0.85) 
0.54 (0.11 to 0.83) 
 
TTF SRE = time to first skeletal related event, TTF+S SRE = time to first and subsequent 
skeletal related events, SMR = skeletal morbidity rate  
  
Table 7: Other solid tumours and non small cell lung cancer NMA results 
 Other solid tumours NSCLC 
TTF SRE 
HR (95%CI) 
TTF+S SRE 
RR (95%CI) 
TTF SRE 
HR (95%CI) 
TTF+S SRE 
RR (95%CI) 
Denosumab versus zoledronic 
acid 
0.79 (0.62 to 0.99) 0.83 (0.67 to 1.03) 0.84 (0.64 to 1.10) 0.87 (0.68 to 1.12) 
Denosumab versus placebo 0.30 (0.11 to 0.82) 0.61 (0.39 to 0.97) 0.68 (0.45 to 1.03) 0.63 (0.42 to 0.97) 
Zoledronic acid versus placebo 0.37 (0.14 to 1.01) 0.74 (0.49 to 1.10) 0.81 (0.59 to 1.11) 0.73 (0.52 to 1.02) 
 
TTF SRE = time to first skeletal related event, TTF+S SRE = time to first and subsequent skeletal related events, SMR = skeletal morbidity rate  
 
 
  
Figure 1: PRISMA flow diagram 
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Figure 2: Breast cancer network diagram 
 
 
 
 
    = direct evidence 
   = indirect evidence from NMA 
Note: Lipton 2000 data was only available for the  SMR outcome. 
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Figure 3: Prostate cancer network diagram 
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Figure 4: Other solid tumours network 
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